Reuters logo
BRIEF-Bristol-Myers provides positive results from Phase 1/2 study Checkmate-032
December 6, 2016 / 2:17 PM / a year ago

BRIEF-Bristol-Myers provides positive results from Phase 1/2 study Checkmate-032

Dec 6 (Reuters) - Bristol-myers Squibb Co

* Press release - opdivo (nivolumab) alone or combined with yervoy (ipilimumab) shows encouraging response and survival rates in recurrent small cell lung cancer, from Phase 1/2 study checkmate -032

* Bristol-Myers Squibb Co - objective response rate with opdivo plus yervoy was 25 pct and was 11 pct with Opdivo monotherapy

* Bristol-Myers Squibb Co - estimated two-year survival rate with combination was 30 pct and was 17 pct with opdivo monotherapy

* Bristol-Myers Squibb Co - confirmed ORR was 25 pct in patients who received opdivo plus yervoy, was 11 pct with opdivo alone with additional follow-up

* Bristol-Myers Squibb Co - grade 3/4 treatment-related discontinuation rates were 10 pct in opdivo plus yervoy group and 4 pct in opdivo group

* Bristol-Myers Squibb Co - no new safety signals were observed with opdivo and opdivo plus yervoy in updated analysis

* Bristol-Myers Squibb Co - in combination arm, three patients experienced a complete response

* Bristol-Myers Squibb-additional efficacy findings included confirmed partial response in 21 patients in opdivo-yervoy arm, 11 patients in opdivo-only arm Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below